about
Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibodySmall animal model systems for studying hepatitis B virus replication and pathogenesis.Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer.Multiplexing clonality: combining RGB marking and genetic barcoding.Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism.A Slow Maturation Process Renders Hepatitis B Virus Infectious.Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression.Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice.Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.Serum HBV pgRNA as a clinical marker for cccDNA activity.A humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells.Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model.Primary human hepatocytes from metabolic-disordered children recreate highly differentiated liver-tissue-like spheroids on alginate scaffolds.Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis BStrong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice[Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany]T cell receptor grafting allows virological control of Hepatitis B virus infectionIn vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice
P50
Q33807794-2E1CE6A1-E3FA-45A4-BDEC-03C4D70F821BQ34318146-709FE45D-F93E-4081-9A23-37D9D0DE5060Q35602284-1429AF95-FDA3-416B-94DC-23D64B877B0EQ36467991-FAB29F3C-3443-4348-B45A-E45126981CBEQ36925733-17E6E2CE-3070-4ECC-9EFA-E71A0AB5AE85Q37701291-10ABD3AE-D508-4C09-B4A5-7F3E4F0310FCQ38665181-494F9471-793B-4BE3-9716-81268374F5CEQ38692495-73102109-7BE1-4E43-903A-199A676BC2FDQ39021951-D4EE5665-E8F1-4397-BE5D-92C8000B903AQ40004593-89CF8A38-6FED-4E70-922D-31A5A484E667Q40183159-1F8AC007-1AA5-4C5A-B438-4B9E00ADD94EQ40383391-5EC2D970-7A14-4711-921E-8F5C8516B5B6Q40820034-E2FC1023-6119-454C-80E7-065B39EDD875Q41399410-893ABD43-8F7C-425D-8CDA-9FEF9902B402Q42239071-D2F85C00-77F9-43F8-83D2-219C38FD1D4EQ42244715-33FC0294-A904-4F93-8B8A-E090CA7476E0Q43040685-E9718A6A-A35D-450A-A108-6CCFCD57A38EQ45323624-5D871CA1-2F64-4370-9C7A-D0C77C4C06BCQ45325559-950EC8FE-CE63-4AE9-B8E1-D8448E603849Q45368507-C4B92FBA-5DE7-473F-98FE-9AF16CF93C21Q45396940-04FF7305-09E2-40CC-BA7F-1C27B791A29BQ47592995-1C508E52-1A20-4AF5-8A35-334173BF5447Q47995614-7DCB152E-22F3-4187-A54E-5B13F2F8AF37Q48204164-513D2507-D27B-403B-AEEC-20E147832A4FQ48504378-DD35C155-776D-40CF-BC82-3818783735E1Q54309107-ADF6B89D-3F43-45D8-8B8A-74515B9544D5Q80188303-9F1A5B35-44F0-4016-8F6B-C6862865FDCFQ83519046-E3A5831B-A133-4CE3-BEE9-AADA3053D712Q85026355-5DE9D5FD-C7F5-4319-848C-B2B8D4E5E024Q91642844-E0E3FD53-27EE-4654-BCE1-43B3074FF055Q95000125-9B0BEFCC-5A48-40C0-8614-AB2900B1CC31
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tassilo Volz
@ast
Tassilo Volz
@en
Tassilo Volz
@es
Tassilo Volz
@nl
type
label
Tassilo Volz
@ast
Tassilo Volz
@en
Tassilo Volz
@es
Tassilo Volz
@nl
prefLabel
Tassilo Volz
@ast
Tassilo Volz
@en
Tassilo Volz
@es
Tassilo Volz
@nl
P106
P31
P496
0000-0003-3120-8958